For example, (a) new drugs such as Finerenone or drugs combinations have been used to delay CKD progression and reduce mortality [97]; (b) strict assessment and intervention regarding vitamin D and the increased availability of phosphorous binders and calcimimetics have been extremely important for PTH control [98]; and (c) LPDs/VLPDs are often used in conjunction with restriction/control of potassium, phosphorus, and sodium intake (as previously mentioned). The gene discussed is PTH; the disease is chronic kidney disease.